DK3768305T3 - Modificerede, onkolytiske adenovira - Google Patents
Modificerede, onkolytiske adenovira Download PDFInfo
- Publication number
- DK3768305T3 DK3768305T3 DK19712178.3T DK19712178T DK3768305T3 DK 3768305 T3 DK3768305 T3 DK 3768305T3 DK 19712178 T DK19712178 T DK 19712178T DK 3768305 T3 DK3768305 T3 DK 3768305T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenoviras
- oncolytic
- modified
- oncolytic adenoviras
- Prior art date
Links
- 230000000174 oncolytic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1804473.5A GB201804473D0 (en) | 2018-03-21 | 2018-03-21 | Modified oncolytic adenoviruses |
| GBGB1814867.6A GB201814867D0 (en) | 2018-03-21 | 2018-09-13 | Modified Oncolytic Adenoviruses |
| PCT/EP2019/056768 WO2019179977A1 (en) | 2018-03-21 | 2019-03-19 | Modified oncolytic adenoviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3768305T3 true DK3768305T3 (da) | 2023-01-23 |
| DK3768305T5 DK3768305T5 (da) | 2024-08-19 |
Family
ID=62017873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19712178.3T DK3768305T5 (da) | 2018-03-21 | 2019-03-19 | Modificerede, onkolytiske adenovira |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210017501A1 (da) |
| EP (1) | EP3768305B1 (da) |
| JP (1) | JP7417533B2 (da) |
| KR (1) | KR102760462B1 (da) |
| CN (1) | CN112118864B (da) |
| AU (1) | AU2019239033B2 (da) |
| CA (1) | CA3094131A1 (da) |
| DK (1) | DK3768305T5 (da) |
| ES (1) | ES2935745T3 (da) |
| FI (1) | FI3768305T3 (da) |
| GB (2) | GB201804473D0 (da) |
| WO (1) | WO2019179977A1 (da) |
| ZA (1) | ZA202005848B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| CN113699122B (zh) * | 2021-08-31 | 2023-10-20 | 中国科学院大学宁波华美医院 | 一种多基因融合溶瘤腺病毒及其构建方法和应用 |
| AU2022349649A1 (en) | 2021-09-23 | 2024-04-04 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU711269B2 (en) * | 1994-08-16 | 1999-10-07 | Crucell Holland B.V. | Recombinant vectors derived from adenovirus for use in gene therapy |
| US7829329B2 (en) * | 1998-04-24 | 2010-11-09 | Onyx Pharmaceuticals, Inc. | Adenoviral vectors for treating disease |
| CA2376314A1 (en) * | 1999-06-07 | 2000-12-14 | The University Of British Columbia | Apoptosis inhibition by adenovirus e3/6.7k |
| EP1218527A2 (en) * | 1999-07-02 | 2002-07-03 | Onyx Pharmaceuticals, Inc. | Adenoviral vectors for treating disease |
| US8940290B2 (en) * | 2008-10-31 | 2015-01-27 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof |
| HUE031689T2 (en) * | 2008-12-22 | 2017-07-28 | Targovax Oy | Oncolytic adenoviral vectors and related procedures and applications |
| RU2012107702A (ru) * | 2009-07-31 | 2013-09-10 | Пэксвэкс, Инк. | Векторы на основе аденовирусов |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| SG10202004535PA (en) * | 2013-04-18 | 2020-06-29 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US10799568B2 (en) * | 2014-05-19 | 2020-10-13 | Valo Therapeutics Oy | Modified adenoviruses for cancer vaccines development |
| TWI636271B (zh) * | 2014-11-20 | 2018-09-21 | 力智電子股份有限公司 | 電池模組的電量量測裝置及方法 |
| US10626377B2 (en) * | 2016-01-08 | 2020-04-21 | Replimune Limited | Use of an oncolytic virus for the treatment of cancer |
| US11090344B2 (en) * | 2016-05-27 | 2021-08-17 | Dnatrix, Inc. | Adenovirus and immunomodulator combination therapy |
| SI3293201T1 (sl) * | 2016-09-12 | 2021-03-31 | Targovax Oy | Kombinacija zaviralcev adenovirusa in zaviralcev kontrolnih točk za zdravljenje raka |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
-
2018
- 2018-03-21 GB GBGB1804473.5A patent/GB201804473D0/en not_active Ceased
- 2018-09-13 GB GBGB1814867.6A patent/GB201814867D0/en not_active Ceased
-
2019
- 2019-03-19 US US17/040,017 patent/US20210017501A1/en active Pending
- 2019-03-19 ES ES19712178T patent/ES2935745T3/es active Active
- 2019-03-19 JP JP2020550115A patent/JP7417533B2/ja active Active
- 2019-03-19 AU AU2019239033A patent/AU2019239033B2/en active Active
- 2019-03-19 EP EP19712178.3A patent/EP3768305B1/en active Active
- 2019-03-19 KR KR1020207029697A patent/KR102760462B1/ko active Active
- 2019-03-19 DK DK19712178.3T patent/DK3768305T5/da active
- 2019-03-19 CN CN201980032730.0A patent/CN112118864B/zh active Active
- 2019-03-19 CA CA3094131A patent/CA3094131A1/en active Pending
- 2019-03-19 FI FIEP19712178.3T patent/FI3768305T3/fi active
- 2019-03-19 WO PCT/EP2019/056768 patent/WO2019179977A1/en not_active Ceased
-
2020
- 2020-09-21 ZA ZA2020/05848A patent/ZA202005848B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112118864A (zh) | 2020-12-22 |
| GB201804473D0 (en) | 2018-05-02 |
| CN112118864B (zh) | 2024-06-25 |
| JP7417533B2 (ja) | 2024-01-18 |
| KR20200135811A (ko) | 2020-12-03 |
| ES2935745T3 (es) | 2023-03-09 |
| FI3768305T3 (fi) | 2023-01-31 |
| JP2021518126A (ja) | 2021-08-02 |
| ZA202005848B (en) | 2022-01-26 |
| AU2019239033B2 (en) | 2025-03-06 |
| RU2020131337A (ru) | 2022-04-28 |
| WO2019179977A1 (en) | 2019-09-26 |
| GB201814867D0 (en) | 2018-10-31 |
| DK3768305T5 (da) | 2024-08-19 |
| BR112020019303A2 (pt) | 2021-01-05 |
| KR102760462B1 (ko) | 2025-01-31 |
| EP3768305B1 (en) | 2022-11-30 |
| CA3094131A1 (en) | 2019-09-26 |
| US20210017501A1 (en) | 2021-01-21 |
| EP3768305A1 (en) | 2021-01-27 |
| AU2019239033A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282985B (en) | Modified oncolytic viurs | |
| EP3833739A4 (en) | STRAIN OF AKKERMANSIA MUCINIPHILA | |
| DK3768305T3 (da) | Modificerede, onkolytiske adenovira | |
| LT3652215T (lt) | Pagerinta dvejopo savitumo polipeptido molekulė | |
| DK3565568T3 (da) | Ændret virus | |
| DK3642340T3 (da) | Modificeret L-asparaginase | |
| HUE062816T2 (hu) | Onkolitikus vakciniavírus | |
| IL282178A (en) | Products, uses & methods | |
| DK3737403T3 (da) | Modificerede adenovira | |
| EP3713931C0 (en) | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE | |
| EP3919491C0 (en) | AKT INHIBITOR | |
| DK3946179T3 (da) | Stomiposer | |
| EP3967649C0 (en) | LIPID NANOPARTICLE | |
| EP3742771C0 (en) | M2M SM-SR TO SM-DP NOTIFICATION | |
| EP3703188A4 (en) | HERMETIC TERMINAL | |
| EP3975220A4 (en) | Display panel | |
| EP3625349A4 (en) | MODIFIED VIRUSES | |
| EP3789489A4 (en) | ANTI-SWEEPER TYPE ONCOLYTIC VIRUS | |
| EP3957391C0 (en) | AGITATOR | |
| EP4041256A4 (en) | Oncolytic viruses that express multi-specific immune cell engagers | |
| EP3965638C0 (en) | VAGINAL SPECULUM | |
| EP3962498A4 (en) | Combination therapies | |
| EP3624825A4 (en) | RECOMBINANT ONCOLYTIC VIRUS | |
| EP3724324C0 (en) | CARBOXYESTERASE BIOCATALYSTS | |
| EP4063289C0 (en) | CROWN CAPSULE |